Tag
The American College of Physicians’ 2026 position paper calls for comprehensive payer coverage, healthy food access, bias reduction, and research to tackle adult obesity through multisector public policy.
A 50-year follow-up of biliopancreatic diversion shows sustained weight loss and diabetes remission, but alarmingly high nutritional complications decades after surgery.
Phase 3a trial in Japan/Taiwan shows cagrilintide-semaglutide combination delivers superior weight loss (18.4%) versus semaglutide alone (11.9%) in adults with overweight/obesity ± type 2 diabetes, with comparable safety profiles dominated
A Phase 1 study of CT-388, a novel signaling-biased dual GLP-1/GIP receptor agonist, demonstrated up to 8% body weight reduction in 28 days with a safety profile consistent with existing incretin therapies, signaling a potential shift in me
A large US cohort study reveals that 14% of bariatric surgery patients start GLP-1 receptor agonists postoperatively, with higher use seen among women, sleeve gastrectomy recipients, and those with greater BMI regain.
Orforglipron, a novel oral GLP-1 receptor agonist, demonstrated significant and sustained weight reduction in obese adults without diabetes in a 72-week phase 3 trial, with a tolerable safety profile consistent with existing GLP-1 therapies
SANA, a nitroalkene derivative of salicylate, enhances creatine-dependent thermogenesis to reduce obesity and improve metabolic health, showing promising safety and efficacy in preclinical and early clinical studies.
Amycretin, a novel dual GLP-1 and amylin receptor agonist, demonstrated safety, tolerability, and dose-proportional pharmacokinetics in adults with overweight or obesity, supporting further trials on its weight loss efficacy.
Maridebart cafraglutide, a novel once-monthly peptide-antibody conjugate, significantly reduces body weight in individuals with obesity, with and without type 2 diabetes, offering a new therapeutic option based on phase 2 trial results.
Eli Lilly’s oral GLP-1 drug orforglipron marks a milestone in obesity treatment, yet competition from novel oral therapies by Novo Nordisk, Viking Therapeutics, Roche, Terns Pharmaceuticals, and Rhythm Pharmaceuticals is intensifying,
